Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ra Pharmaceuticals, a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation and for orphan indications, today announced that data from the Company‚Äôs Phase 1 trial of its lead product candidate, RA101495, a synthetic macrocyclic peptide inhibitor of complement C5 for paroxysmal nocturnal hemoglobinuria (PNH), will be presented at the 21st Congress of the European Hematology
Source: BusinessWire-Primary

Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association